Stanford University
Showing 31-40 of 80 Results
-
Bin Han
Clinical Professor, Radiation Oncology - Radiation Physics
Current Research and Scholarly InterestsDevelopment of an advanced EPID-based dosimetric solution
Ultrasound system for image guided prostate cancer treatment,
Depth sensing and 3D-printing techniques for total body irradiation
AI applications in predicting treatment effectiveness and cancer recurrence -
Steven Hancock, MD
Professor of Radiation Oncology (Radiation Therapy), Emeritus
Current Research and Scholarly InterestsOutcomes of radiation treatment for prostate cancer. Clinical research interests in the late effects of radiation on normal tissues and chemical modification of radiation injury. Hodgkins's disease and late effects of radiation and combined modality therapy. Radiation sensitizers. Hypoxic cell cytotoxins. Esophageal cancers.
General adult and pediatric radiation therapy. -
Richard Hoppe
Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
Current Research and Scholarly InterestsIrradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma;, mycosis fungoides.
-
Dimitre Hristov
Associate Professor of Radiation Oncology (Radiation Physics)
On Leave from 02/03/2025 To 03/11/2025Current Research and Scholarly InterestsDevelopment and integration of X-ray, MRI and US imaging technologies for radiation therapy guidance; Design of synergistic approaches to radiation therapy delivery; Treatment planning optimization and modeling.
-
Anusha Kalbasi, MD
Associate Professor of Radiation Oncology (Radiation Therapy)
BioDr. Kalbasi is a board-certified radiation oncologist and physician-scientist at the Stanford Cancer Institute. He is also an associate professor of radiation oncology at Stanford Medicine and a project member of the Parker Institute for Cancer Immunotherapy.
In the clinic, Dr. Kalbasi specializes in the diagnosis and treatment of solid tumors, especially sarcoma and melanoma, with a focus on bringing new treatments to patients. This focus includes using advanced techniques in radiation oncology and cancer immunotherapy.
Dr. Kalbasi's NIH-funded laboratory studies the cancer-immune interface in various therapeutic contexts, including T cell therapy, cytokine therapy and innate immune agonism. The lab has described tumor cell-, T cell- and myeloid cell-intrinsic mechanisms of resistance to therapy and approaches to overcome therapy resistance. Dr. Kalbasi is also an experienced leader of clinical trials related to immunotherapy, T cell therapy and radiation therapy.
Prior to his arrival at Stanford Health Care, Dr. Kalbasi was assistant professor of radiation oncology in the David Geffen School of Medicine at UCLA and chief of sarcoma radiotherapy at the UCLA Jonsson Comprehensive Cancer Center. During his tenure, he was named a NextGen Star by the American Association of Cancer Research in recognition for excellence in cancer research.
Dr. Kalbasi’s work has been published in leading journals including Nature, Science Translational Medicine, JAMA Oncology, Lancet Oncology, Nature Cancer and Cancer Discovery. He has served as a peer reviewer for multiple prestigious journals, including the Proceedings of the National Academy of Sciences, Cell and the Journal of Clinical Investigation. He has also presented research to his peers at the American Association for Cancer Research and the American Institute of Chemical Engineers. -
Daniel Kapp
Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsGynecologic malignancies; Rectal/and cancer; Breast Cancer; Hodgkin's disease; Hyperthermia; intraoperative radiation therapy; High dose rate radiation therapy; Predictive assays; Patterns of tumor spread; Health care finance.
